Reduction in Mortality after Umbilical Cord Blood Transplantation in Children over a 20-Year Period (1995-2014)

Allogeneic hematopoietic stem cell transplantation is used to treat a growing number of malignant and non-malignant conditions in children. When available, bone marrow from a human leukocyte antigen (HLA)-matched sibling is the preferred donor source for allogeneic stem cell transplantation. However, less than 40% of children requiring a stem cell transplant have a matched sibling donor [1]. Banked unrelated donor umbilical cord blood has been utilized for the past 25 years as an alternative donor for patients lacking a matched sibling or matched unrelated adult donor [2].

Source: Biology of Blood and Marrow Transplantation - November 24, 2018 Category: Hematology Authors: Lisa Spees, Paul L. Martin, Joanne Kurtzberg, Andre Stokhuyzen, Lauren McGill, Vinod K. Prasad, Timothy A. Driscoll, Suhag H. Parikh, Kristin M. Page, Richard Vinesett, Christopher Severyn, Anthony D. Sung, Alan D. Proia, Kirsten Jenkins, Mehreen Arshad, Source Type: research